Cipla shares ratings cut by Morgan Stanley, CLSA on earnings
- Sreesanth, Jiju Janardhan lived in independently booked rooms: Cops
- India to convey concerns over Ladakh incursion to Chinese Premier
- IPL 2013 LIVE SCORE: Maxwell falls early in stiff run-chase
- Narendra Modi: India losing sheen as agricultural nation
- Rajapaksa slams Tamil diaspora for lack of support in reconciliation process
Morgan Stanley and CLSA downgraded their ratings on Cipla Ltd shares a day after the Indian drugmaker reported a slower-than-expected rise in its October-December net profit.
Morgan Stanley cut its ratings to "equal-weight" from "overweight", citing slower growth prospects on the back of limited niche drug launches, lower margins and a higher tax rate. The bank also cut its price target to 414 rupees from 437 rupees.
CLSA cut its ratings on Cipla to "underperform" from "outperform", citing disappointing margins in the October-December quarter and expectations near-term earnings growth will be slower due a higher base. The bank cut its price target to 415 rupees from 475 rupees.
- Destitute, orphan students outclass rest in Andhra Class 10 exams
- To re-energise ties, PM wants to visit US, waits for confirmation
- NIA court says no terror link, frees 'Hizbul militant' Liyaqat on bail
- CBI arrests its coal allotments investigator on bribery charge
- ‘Cricketer-bookie Amit may have used Jiju to reach Sree’
- BCCI chief N Srinivasan says police must prove spot-fixing allegations